1.
Rev Esp Enferm Dig
; 116(1): 43, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37073695
RESUMO
New immunosuppressive and antineoplastic drugs are becoming both more numerous and more widely used, even during several years. Most of them present a low-moderate risk of hepatitis B virus (HBV) reactivation in HBsAg-negative and anti-HBc-positive patients. However, their reactivation capacity has not been clearly studied. We present the clinical case of a patient with these serological characteristics who, after 5 years of treatment with ibrutinib for chronic lymphocytic leukaemia, developed VHB reactivation, which was controlled with tenofovir. The occurrence of this event with drugs such as ibrutinib may lead to changes in HBV reactivation prophylaxis.
Assuntos
Adenina/análogos & derivados , Vírus da Hepatite B , Hepatite B , Humanos , Hepatite B/induzido quimicamente , Antígenos de Superfície da Hepatite B , Piperidinas/farmacologia , Piperidinas/uso terapêutico , Ativação Viral , Antivirais/efeitos adversos
2.
Reactivación del virus de la hepatitis B por ibrutinib / Hepatitis B virus reactivation by ibrutinib
Rev. esp. enferm. dig
; 116(1): 43-43, 2024.
Artigo
em Espanhol
| IBECS
| ID: ibc-229484
3.
Br J Haematol
; 177(5): 816-818, 2017 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27125335
4.
Med Clin (Barc)
; 131(19): 757-8, 2008 Nov 29.
Artigo
em Espanhol
| MEDLINE
| ID: mdl-19091207
5.
Med. clín (Ed. impr.)
; 131(19): 757-758, nov. 2008.
Artigo
em Es
| IBECS
| ID: ibc-69592
RESUMO
No disponible
